Can Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Can Li has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Jiuliang Zhao
Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China
2 shared publications Yan Zhao
Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China
2 shared publications- Yan Zhao
Department of Rheumatology and Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
2 shared publications - Bin Zhang
Institute for Immunology and School of Medicine, Tsinghua University, Beijing, China 1
1 shared publication - Chanyuan Wu
Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital; Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing 100032, China
1 shared publication Cheng Cui
Department of Cardiology, Fuwai Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China
1 shared publication
Latest Publications
- 17 August 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
Feasibility of Distal Radial Artery Interventions and Impact of Radial Artery Diameter on Puncture Failure
Background: The widespread adoption of distal radial artery (DRA) interventions has been limited by the relatively higher puncture difficulty compared to conventional radial artery access. Aims: Evaluate the feasibility of DRA access and explore relationship between radial artery diameter and puncture failure. Methods: A total of 733 patients proposed for DRA access were enrolled at the Department of Cardiology, Fuwai Hospital, between 2021 and 2024. All patients underwent preoperative ultrasound evaluation to measure the radial artery diameter at the snuffbox, and at 5 cm, 10 cm, and 15 cm proximal to the styloid process of the radius. The primary outcome was DRA puncture failure. Results: The overall DRA puncture success rate among these patients was 96.6%. PCI was performed in 74.0% of cases, with a procedural success rate of 92.7%. Multivariate logistic regression analysis showed that DRA diameter at the snuffbox was significantly associated with puncture failure (OR = 0.24; 95% CI: 0.09–0.61). Restricted cubic spline analysis (RCS) demonstrated a nonlinear association between DRA diameter at the snuffbox and puncture failure, with an increased risk observed as DRA diameter decreased below approximately 2.40 mm. Notably, segmented logistic regression identified an inflection point at 1.67 mm, below which the risk of puncture failure increased significantly. Conclusion: The feasibility of DRA access was demonstrated in our study. DRA diameter was identified as an important predictor of puncture success. These findings provide an anatomical consideration for patient selection and may assist clinicians in optimizing the use of DRA access in future interventions.
- 17 August 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
Feasibility of Distal Radial Artery Interventions and Impact of Radial Artery Diameter on Puncture Failure
Background: The widespread adoption of distal radial artery (DRA) interventions has been limited by the relatively higher puncture difficulty compared to conventional radial artery access. Aims: Evaluate the feasibility of DRA access and explore relationship between radial artery diameter and puncture failure. Methods: A total of 733 patients proposed for DRA access were enrolled at the Department of Cardiology, Fuwai Hospital, between 2021 and 2024. All patients underwent preoperative ultrasound evaluation to measure the radial artery diameter at the snuffbox, and at 5 cm, 10 cm, and 15 cm proximal to the styloid process of the radius. The primary outcome was DRA puncture failure. Results: The overall DRA puncture success rate among these patients was 96.6%. PCI was performed in 74.0% of cases, with a procedural success rate of 92.7%. Multivariate logistic regression analysis showed that DRA diameter at the snuffbox was significantly associated with puncture failure (OR = 0.24; 95% CI: 0.09–0.61). Restricted cubic spline analysis (RCS) demonstrated a nonlinear association between DRA diameter at the snuffbox and puncture failure, with an increased risk observed as DRA diameter decreased below approximately 2.40 mm. Notably, segmented logistic regression identified an inflection point at 1.67 mm, below which the risk of puncture failure increased significantly. Conclusion: The feasibility of DRA access was demonstrated in our study. DRA diameter was identified as an important predictor of puncture success. These findings provide an anatomical consideration for patient selection and may assist clinicians in optimizing the use of DRA access in future interventions.
- Open Access
- 11 January 2022
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 219 (2)
CD127 imprints functional heterogeneity to diversify monocyte responses in inflammatory diseases
Inflammatory monocytes are key mediators of acute and chronic inflammation; yet, their functional diversity remains obscure. Single-cell transcriptome analyses of human inflammatory monocytes from COVID-19 and rheumatoid arthritis patients revealed a subset of cells positive for CD127, an IL-7 receptor subunit, and such positivity rendered otherwise inert monocytes responsive to IL-7. Active IL-7 signaling engaged epigenetically coupled, STAT5-coordinated transcriptional programs to restrain inflammatory gene expression, resulting in inverse correlation between CD127 expression and inflammatory phenotypes in a seemingly homogeneous monocyte population. In COVID-19 and rheumatoid arthritis, CD127 marked a subset of monocytes/macrophages that retained hypoinflammatory phenotypes within the highly inflammatory tissue environments. Furthermore, generation of an integrated expression atlas revealed unified features of human inflammatory monocytes across different diseases and different tissues, exemplified by those of the CD127high subset. Overall, we phenotypically and molecularly characterized CD127-imprinted functional heterogeneity of human inflammatory monocytes with direct relevance for inflammatory diseases.
- 11 January 2022
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 219 (2)
Open AccessCD127 imprints functional heterogeneity to diversify monocyte responses in inflammatory diseases
Inflammatory monocytes are key mediators of acute and chronic inflammation; yet, their functional diversity remains obscure. Single-cell transcriptome analyses of human inflammatory monocytes from COVID-19 and rheumatoid arthritis patients revealed a subset of cells positive for CD127, an IL-7 receptor subunit, and such positivity rendered otherwise inert monocytes responsive to IL-7. Active IL-7 signaling engaged epigenetically coupled, STAT5-coordinated transcriptional programs to restrain inflammatory gene expression, resulting in inverse correlation between CD127 expression and inflammatory phenotypes in a seemingly homogeneous monocyte population. In COVID-19 and rheumatoid arthritis, CD127 marked a subset of monocytes/macrophages that retained hypoinflammatory phenotypes within the highly inflammatory tissue environments. Furthermore, generation of an integrated expression atlas revealed unified features of human inflammatory monocytes across different diseases and different tissues, exemplified by those of the CD127high subset. Overall, we phenotypically and molecularly characterized CD127-imprinted functional heterogeneity of human inflammatory monocytes with direct relevance for inflammatory diseases.
- 19 November 2020
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 60 (5) , 2288-2295
The long-term prognosis of pneumomediastinum associated with dermatomyositis: a two-centre retrospective cohort study
Objectives: Pneumomediastinum (PnM) is a rare but life-threatening complication of DM. The present study aims to characterize the long-term prognosis and prognostic factors of DM-associated PnM. Methods: Inpatients with DM-associated PnM were retrospectively enrolled from two tertiary referral centres for rheumatic disease. The enrolled patients were divided into survivors or non-survivors. Information about the demographics, clinical manifestations, CT scan features, laboratory findings and outcomes were collected from their medical records. A least absolute shrinkage and selection operator regularized Cox regression model was used to select the most relevant factors. Prognosis was analysed using a Kaplan–Meier curve. A Cox proportional hazards model was used to identify independent predictive factors for long-term survival. Results: A total of 62 patients (26 women) with DM-associated PnM were enrolled. The mean age was 44.3 years (s.d. 11.7). The median follow-up duration was 17 days (quartiles 7, 266.5). Thirty-five patients died during follow-up. The survival rates were 75.4% at 1 week, 46.2% at 3 months and 41.9% at 1 year. The Cox proportional hazards model identified the development of fever [hazard ratio (HR) 3.23 (95% CI 1.25, 8.35), P = 0.02] and a decrease in the number of lymphocytes [HR 2.19 (95% CI 1.10, 4.39), P = 0.03] as independent risk factors for death. Conclusion: The results suggest poor overall survival among patients with DM-associated PnM. Survival during the first 3 months is crucial for long-term survival. Meanwhile, the development of fever and a decrease in the number of lymphocytes were associated with long-term mortality. Early recognition and prompt treatment of this high-risk group of DM patients is therefore important.
- 19 November 2020
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 60 (5) , 2288-2295
The long-term prognosis of pneumomediastinum associated with dermatomyositis: a two-centre retrospective cohort study
Objectives: Pneumomediastinum (PnM) is a rare but life-threatening complication of DM. The present study aims to characterize the long-term prognosis and prognostic factors of DM-associated PnM. Methods: Inpatients with DM-associated PnM were retrospectively enrolled from two tertiary referral centres for rheumatic disease. The enrolled patients were divided into survivors or non-survivors. Information about the demographics, clinical manifestations, CT scan features, laboratory findings and outcomes were collected from their medical records. A least absolute shrinkage and selection operator regularized Cox regression model was used to select the most relevant factors. Prognosis was analysed using a Kaplan–Meier curve. A Cox proportional hazards model was used to identify independent predictive factors for long-term survival. Results: A total of 62 patients (26 women) with DM-associated PnM were enrolled. The mean age was 44.3 years (s.d. 11.7). The median follow-up duration was 17 days (quartiles 7, 266.5). Thirty-five patients died during follow-up. The survival rates were 75.4% at 1 week, 46.2% at 3 months and 41.9% at 1 year. The Cox proportional hazards model identified the development of fever [hazard ratio (HR) 3.23 (95% CI 1.25, 8.35), P = 0.02] and a decrease in the number of lymphocytes [HR 2.19 (95% CI 1.10, 4.39), P = 0.03] as independent risk factors for death. Conclusion: The results suggest poor overall survival among patients with DM-associated PnM. Survival during the first 3 months is crucial for long-term survival. Meanwhile, the development of fever and a decrease in the number of lymphocytes were associated with long-term mortality. Early recognition and prompt treatment of this high-risk group of DM patients is therefore important.
- Open Access
- 1 July 2019
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 46 (7) , 755-756
Hepatic Infarction Caused by Antiphospholipid Syndrome Secondary to Systemic Lupus Erythematosus
- 1 July 2019
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 46 (7) , 755-756
Open AccessHepatic Infarction Caused by Antiphospholipid Syndrome Secondary to Systemic Lupus Erythematosus
- 19 November 2018
- Published by SAGE Publications in Lupus
- Vol. 27 (14) , 2206-2214
Pulmonary thromboendarterectomy is a curative resolution for chronic thromboembolic pulmonary hypertension associated with antiphospholipid syndrome: a retrospective cohort study
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare and life-threatening condition with poor prognosis in patients with antiphospholipid syndrome (APS). Pulmonary thromboendarterectomy (PTE) is the optimal surgical option for CTEPH. This retrospective cohort study aimed to evaluate the efficacy and risk of PTE in patients with APS-associated CTEPH. Consecutive patients with APS-associated CTEPH diagnosed between January 2012 and September 2017 at Peking Union Medical College Hospital were retrospectively evaluated. Demographics, clinical manifestations, antiphospholipid antibody (aPL) profiles, and pulmonary arterial hypertension–targeted medications were collected. Deterioration of cardiac function and death were chosen as the endpoints, in order to assess the effect of PTE on short-term and long-term prognoses (evaluated by the change of cardiac function after treatment and cardiac deterioration or death in the follow-up, respectively). A total of 20 patients with APS-associated CTEPH were enrolled, and eight patients underwent PTE. Chi-square test (p = 0.01) and Kaplan–Meier curves (log rank test, p = 0.04) showed that there were statistically significant differences in both short-term and long-term prognoses between patients with and without PTE. These results provide strong evidence that PTE is a curative resolution in patients with APS-associated CTEPH. Following a full specialized and multidisciplinary risk-benefit evaluation to limit the risk of thrombosis or bleeding and to manage possible thrombocytopenia, PTE is at least a temporal curative resolution for CTEPH complicated with APS.
- 19 November 2018
- Published by SAGE Publications in Lupus
- Vol. 27 (14) , 2206-2214
Pulmonary thromboendarterectomy is a curative resolution for chronic thromboembolic pulmonary hypertension associated with antiphospholipid syndrome: a retrospective cohort study
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare and life-threatening condition with poor prognosis in patients with antiphospholipid syndrome (APS). Pulmonary thromboendarterectomy (PTE) is the optimal surgical option for CTEPH. This retrospective cohort study aimed to evaluate the efficacy and risk of PTE in patients with APS-associated CTEPH. Consecutive patients with APS-associated CTEPH diagnosed between January 2012 and September 2017 at Peking Union Medical College Hospital were retrospectively evaluated. Demographics, clinical manifestations, antiphospholipid antibody (aPL) profiles, and pulmonary arterial hypertension–targeted medications were collected. Deterioration of cardiac function and death were chosen as the endpoints, in order to assess the effect of PTE on short-term and long-term prognoses (evaluated by the change of cardiac function after treatment and cardiac deterioration or death in the follow-up, respectively). A total of 20 patients with APS-associated CTEPH were enrolled, and eight patients underwent PTE. Chi-square test (p = 0.01) and Kaplan–Meier curves (log rank test, p = 0.04) showed that there were statistically significant differences in both short-term and long-term prognoses between patients with and without PTE. These results provide strong evidence that PTE is a curative resolution in patients with APS-associated CTEPH. Following a full specialized and multidisciplinary risk-benefit evaluation to limit the risk of thrombosis or bleeding and to manage possible thrombocytopenia, PTE is at least a temporal curative resolution for CTEPH complicated with APS.